SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies (BMNR) is facing intense investor debate ahead of its critical shareholder meeting regarding a proposed massive increase in authorized shares and a new investment in Beast Industries. The community is sharply divided, fearing significant dilution and the stock's continued underperformance against Ethereum, while others believe these controversial moves are crucial for strategic growth. High-profile speakers at the upcoming meeting, including Vitalik Buterin and Sam Altman, are further fueling speculation about the company's future direction.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial (RILY) is trending on news of its Q3 10-Q filing, which reveals a significant swing to profitability, substantial debt reduction, and regained NASDAQ compliance. This positive fundamental shift is fueling widespread discussion of a major short and gamma squeeze, given the high short interest and limited float, with many anticipating a significant upward move as a potential turnaround story.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor Manufacturing is trending strongly after delivering an impressive earnings report that surpassed expectations, fueled by robust demand for advanced AI chips. The semiconductor giant's optimistic guidance and substantial capital expenditure plans are widely viewed by the community as a powerful affirmation of the accelerating AI infrastructure build-out. This performance is boosting sentiment across the broader semiconductor sector and reinforcing confidence in the long-term AI megatrend.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending amid intense community discussion around a potential gamma squeeze driven by significant options activity. Investors are highly optimistic about its Optical Interposer platform, which is poised to revolutionize high-speed optical interconnects for the booming AI and data center sectors. Despite a recent quiet period from management, speculation about imminent news and major partnership developments is fueling strong bullish sentiment for its disruptive technology.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is a top trending stock amid a flurry of updates regarding its strategic AI infrastructure buildout, including a major BlackRock partnership for data centers and a new initiative to cover associated utility costs for local communities. The community is buzzing with both bullish sentiment ahead of upcoming earnings, anticipating a rebound from recent dips, and bearish concerns about intense AI competition and the scale of investment required. This positions Microsoft at the heart of the broader conversation around AI monetization and hyperscaler growth within the tech sector.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending amid renewed speculation that Sanofi is preparing a higher takeover offer after the company's board rejected an earlier bid. The community broadly interprets this rejection as strong confidence in Ocular's late-stage wet AMD drug, AXPAXLI, and its broader pipeline. Investors are actively discussing potential increased buyout valuations, bolstered by an accelerated regulatory pathway and the drug's anticipated efficacy.

High Roller Technologies, Inc. is an evolving and growth-oriented iCasino and entertainment company, which engages in the business of operating an online gaming business offering casino betting games to customers. The firm also offers a wide range of games including many that are available in land-based casinos, such as blackjack, roulette, baccarat, poker, and slot machines. The company was founded by Michael Alexander Cribari and Brandon Christopher Eachus on December 21, 2021 and is headquartered in Las Vegas, NV.

High Roller Technologies Inc.

High Roller Technologies Inc

High Roller Technologies (ROLR) is trending due to its strategic expansion into the prediction markets space through significant partnerships, including a collaboration with Crypto.com. The community is sharply divided, with bulls anticipating a multi-day runner and short squeeze reminiscent of other parabolic stocks, while bears warn of an imminent offering and unsustainable gains, classifying the move as a pump and dump.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X Shares

Direxion Daily Semiconductor Bull 3X Shares

SOXL is seeing a significant surge, fueled by robust sentiment surrounding strong semiconductor earnings reports from key industry players and the accelerating demand from the AI buildout. The community is actively discussing the sustained upward momentum and potential for continued gains, reflecting broader market optimism for the semiconductor sector's ongoing expansion, while acknowledging the leveraged nature of the product.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is a trending topic following its profit results, which surpassed expectations thanks to robust performance in equities trading and asset and wealth management. The market is weighing this core business strength and a dividend increase against a revenue shortfall, largely due to its strategic departure from the Apple Card portfolio. Community discussion highlights the firm's focus on institutional banking while some question broader bank sector movements.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending following its recent 100% dividend increase and an optimistic production outlook for 2025-2026, anticipating substantial profitability at higher silver prices. While many are accumulating on dips, the community is actively debating the stock's pronounced volatility and perceived underperformance relative to silver's rapid ascent, attributing the lag to ongoing market manipulation. Despite these frustrations, a strong conviction remains that AG is significantly undervalued, poised for an explosive catch-up rally as fundamentals assert themselves against current market dynamics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Artelo Biosciences, Inc. (ARTL) surged 57% on Monday afternoon after the company announced positive preclinical data highlighting the potential of its drug candidate in treating depression and anxiety.The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with leading antidepressant medication, Sertraline (Zoloft).ART12.11 <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.artelobio.com/news-events/press-releases/detail/153/artelo-biosciences-announces-positive-preclinical-efficacy">improved</a> sucrose preference and social motivation, which are established behavioral markers of depressive-like states, to near-baseline levels.However, unlike Sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory, the company added.<a href="https://stocktwits.com/symbol/ARTL">Artelo</a> added that the findings demonstrate the candidate’s potential as a candidate for treating depression and anxiety, especially in patients where cognitive dysfunction occurs, which is a known limitation of existing selective serotonin reuptake inhibitor therapies like Sertraline.ART12.11 is Artelo’s wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP).Prior preclinical research studies in animals with ART12.11 demonstrated greater behavioral and pharmacokinetic results compared to Cannabidiol or Epidiolex.Artelo CEO Gregory D Gorgas said that although strong antidepressant effects were noted with ART12.11 in prior studies, the company is “especially encouraged” by these new comparative findings.On Stocktwits, retail sentiment around Artelo, however, fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_12_27_08_PM_png_b2e63d4064.webp" alt="ARTL's Sentiment Meter and Message Volume as of 12:27 p.m. ET on July 7, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>ARTL's Sentiment Meter and Message Volume as of 12:27 p.m. ET on July 7, 2025 | Source: Stocktwits</figcaption></figure>ARTL stock is up by about 148% this year and by about 99% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/retail-buying-hit-3-4-trillion-in-the-first-half-of-2025-yet-market-chatter-has-faded/chFtYldR5fx">Retail Buying Hit $3.4 Trillion In The First Half Of 2025, Yet Market Chatter Has Faded</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug

The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft). 

Equity

The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft). 


Shares of Artelo Biosciences, Inc. (ARTL) more than doubled on Monday after the company announced favorable results from its first in-human study evaluating ART26.12, a non-opioid treatment candidate for persistent pain.ART26.12 is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). CIPN is nerve damage caused by certain chemotherapy drugs, leading to sensory, motor, or autonomic dysfunction.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/30/3107392/0/en/Artelo-Biosciences-Announces-Positive-First-in-Human-Data-for-ART26-12-a-Novel-Non-Opioid-Treatment-Candidate-for-Persistent-Pain.html">said</a> that all adverse events identified during the in-human trial were mild, transient, and self-resolving. Furthermore, the study demonstrated predictable pharmacokinetics for the drug.Pharmacokinetics is defined as the quantitative analysis of the processes of drug absorption, distribution, and elimination that determine the time course of drug action in response to an administered drug dose.The company said that complete dose-exposure profiles were explored, and tests confirmed dose-dependent, linear absorption across the evaluated range.Andrew Yates, Chief Scientific Officer at Artelo, said that the company is “particularly pleased” that the safety and pharmacokinetic profile generated from ART26.12’s non-clinical studies translated well to the human experience.According to Artelo, the chronic pain therapeutics market exceeded $97 billion globally in 2023 and is expected to surpass $159 billion by 2030, driven by the increasing prevalence of conditions such as neuropathic pain, arthritis, and fibromyalgia.The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.On Stocktwits, retail sentiment around ARTL jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_30_at_1_46_11_PM_png_54bfa7b48c.webp" alt="ARTL's Sentiment Meter and Message Volume as of 1:45 p.m. ET on June 30, 2025 | Source: Stocktwits" width="624" height="62"><figcaption>ARTL's Sentiment Meter and Message Volume as of 1:45 p.m. ET on June 30, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user, however, flagged that the company will need cash to progress its pipeline, and hence, dilution is likely.<stembedurl>https://stocktwits.com/ElPutoToro/message/619463192</stembedurl>The company had cash and investments totaling only $0.7 million as of the end of the first quarter.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up by about 135% this year and by about 85% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-q2-deliveries-expected-to-fall-below-consensus-jpmorgan-underscores-sizable-shortfall/chmZF6zRR7Q">Tesla Q2 Deliveries Expected To Fall Below Consensus, JPMorgan Underscores A ‘Sizable’ Shortfall</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artelo Biosciences Stock Doubles After Positive Results In First Non-Opioid Pain Treatment Trial

Shares of Artelo Biosciences, Inc. (ARTL) more than doubled on Monday after the company announced favorable results from its first in-human study evaluating ART26.12, a non-opioid treatment candidate for persistent pain.

The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.


Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

Artelo Biosciences Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

ARTL
Artelo Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ARTL News

ARTLArtelo Biosciences Inc